



TECHNICAL BULLETIN

☒ **NEW TEST** ☐ **TEST CHANGE**

NOTIFICATION DATE: 09/19/2022

EFFECTIVE DATE: 9/27/2022

PSA with Risk Stratification and PSA with Risk (Medicare)

Northwell Health Laboratories, in partnership with Northwell Health's Smith Institute for Urology, is pleased to announce the availability of new prostate-specific antigen (PSA) tests that also will provide a calculated likelihood (i.e., risk estimate) of identifying high-grade prostate cancer in men if a prostate biopsy were to be performed. These tests are intended to be utilized in men (age greater than 55 years old) without a previous diagnosis of prostate cancer to determine the need for a prostate biopsy by their urologist.

The estimated likelihood of high-grade prostate cancer is derived from a multinomial logistic regression model that incorporates defined patient's clinical characteristics (age, PSA concentration, digital rectal exam, African ancestry, family history of prostate cancer, and prior negative biopsy) and is based on clinical studies conducted at multiple diverse North American and European research institutions [1].

Test Parameters	PSA with Risk Stratification	PSA with Risk (Medicare)
Method	Electrochemiluminescent Immunoassay	Electrochemiluminescent Immunoassay
Submission Container/Tube	Gold Top Tube	Gold Top Tube
Specimen Volume:	1.0 mL Serum	1.0 mL Serum
Storage Instruction	Refrigerated	Refrigerated
Computer Interface Code	PDM# 2153040	PDM# 2153041
Test Code	PSARISK	PSASCRRISK
CPT Code	84153	G0103

If you have any questions, please contact Client Services at (516) 719-1100.

1. Ankerst et al. Eur Urol. 2018 Aug; 74(2): 197–203. <https://doi.org/10.1016/j.eururo.2018.05.003>
2. <http://riskcalc.org:3838/PBCG/>